Leukemia Clinical Trials in Houston

Showing 1221-1240 of 1,435 trials

WITHDRAWNPhase 1< 1 mile

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

NCT00732186

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

Leukemia, Myeloid, Chronic

Bristol-Myers SquibbStarted Aug 2009

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

NCT01390402

The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML. The safety of this treatment will also be studied.

LeukemiaChronic Myelogenous Leukemia

M.D. Anderson Cancer Center6 participantsStarted Jan 2012

Houston, Texas, United States

COMPLETEDPhase 3< 1 mile

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112294

The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.

Non-Small-Cell Lung Carcinoma

Eli Lilly and Company755 participantsStarted Dec 2004

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +121 more locations

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Leukemia Trials in Other Cities

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Other Conditions in Houston